The FDA’s approval of generic liraglutide is about more than reducing drug prices—it’s part of a larger effort to address significant challenges in the pharmaceutical industry.

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 medication injected daily instead of weekly.

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announced that human study GLP-1-H25-5 which ...

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule ...

Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda(R)) Lexaria has now demonstrated, in distinct ...

Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world ...

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule ACCESS Newswire - Wed Jun 11, 4:05AM CDT ...